VRAX NASDAQ
Virax Biolabs Group Limited
1W: -8.3%
1M: -13.7%
3M: -29.3%
YTD: +472.9%
1Y: +255.2%
3Y: -29.0%
$2.20
-0.04 (-1.79%)
Weekly Expected Move ±9.1%
$2
$2
$2
$2
$3
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$0.4M
52W Range2.04-21.75
Volume19,199
Avg Volume1,393,869
Beta1.35
Dividend—
Analyst Ratings
Company Info
CEOJames Foster
Employees26
SectorHealthcare
IndustryBiotechnology
IPO Date2022-07-21
Websiteviraxbiolabs.com
BioCity Glasgow
Lanarkshire, SC ML1 5UH
GB
Lanarkshire, SC ML1 5UH
GB
44 20 7788 7414
About Virax Biolabs Group Limited
Virax Biolabs Group Limited is a biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. The company is developing T cell-based test technologies intended to support an immunology profiling platform, with potential applications in post-acute infection syndromes, including Long COVID, and other chronic conditions linked to immune dysregulation.
Latest News
Virax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross Proceeds
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| HAIGHT NELSON M | 10,000 | $0.68 | 2026-03-18 | |
| HAIGHT NELSON M | 10,000 | $0.88 | 2026-03-18 | |
| HAIGHT NELSON M | 2,000 | $15.40 | 2026-03-18 | |
| HAIGHT NELSON M | 10,000 | $6.00 | 2026-03-18 | |
| McCracken Nigel Will | 50,000 | $0.68 | 2026-03-18 |